Agilent Technologies, the Santa Clara-based biotech research leader, partnered with Turner Construction for the expansion of its manufacturing facility in Frederick, Colorado. Valued at $725 million, this 200,000-square-foot project is set to elevate Agilent’s capacity to meet the growing demand for its synthetic oligonucleotides, essential in treating cancer, cardiovascular disease, and other rare conditions. With the synthetic oligonucleotides market projected to experience double-digit annual growth over the next five years, reaching approximately $2.4 billion in 2027, this expansion is not only a strategic move for Agilent but a significant contribution to advancing biotechnological solutions.
Turner Construction, serving as the general contractor, alongside Fluor Corp. and CRB, is set to incorporate cutting-edge engineering enhancements, including advanced automation and solvent capturing, to expedite the completion of this state-of-the-art manufacturing facility.
